Sarah Cannon Research Institute

We are excited to share the latest installment in our Rediscover SCRI Recruiting Series, spotlighting the incredible journey of our colleague, Penny.   Penny's story with Sarah Cannon Research Institute (SCRI) began in September 2009. From her initial role supporting studies—ranging from submitting letters of intent to the FDA, managing studies, to study closures and archives—Penny has always been a dedicated member of our team.   After a two-year stint as a Research Study Coordinator at a local hospital, Penny rejoined SCRI in June 2015. Her diverse research background and site perspective have been invaluable to our Quality Assurance team supporting Sarah Cannon Development Innovations.   Penny says, "The colleagues I have worked with at Sarah Cannon put participant safety first. I feel blessed to be a part of a team that is professional and cognizant of the importance of participant safety, communication, and documentation."   Penny’s commitment to participant safety and her diverse research experience embody the core values that make SCRI a leader in healthcare innovation. We are grateful to have her as part of our team and look forward to her continued contributions.   Join us in celebrating Penny’s inspiring journey and dedication to research excellence! 🎉   Are you inspired by Penny's story? Explore exciting career opportunities with SCRI and become part of a team that values excellence and innovation. Visit our careers page to learn more: https://lnkd.in/e5hFN2ri   #SCRI #RediscoverSCRI #ResearchExcellence #HealthcareInnovation #TeamSpotlight #ParticipantSafety #PatientCare

October is Patient-Centered Care Awareness Month. At Sarah Cannon Research Institute, patients are at the heart of everything we do. This month, we’re highlighting a few of the many voices of our dedicated physicians who play a crucial role in ensuring patients not only have access to cutting-edge advancements but also receive the personalized care they need. Swipe through to hear from Dr. Mark Fleming, Cesar Perez M.D., Erika Hamilton, MD, Ishwaria Subbiah, MD, MS, FASCO, and Dr. Charles Anderson, on why clinical trials are essential to delivering patient-centered care. #PatientCare #ClinicalTrials

We’ve seen promising advancements in breast cancer treatment over the past decade, but there’s still more work to be done. Erika Hamilton, MD, Chair, Breast Executive Committee Director, Breast Cancer Research Program Sarah Cannon Research Institute shares her insights into the latest trends she’s seeing and the implications for women.   Watch her interview with Contemporary OB/GYN below.

We are thrilled to welcome Dr. Deepak Bhamidipati as our new Assistant Director of Drug Development at Sarah Cannon Research Institute (SCRI)! Dr. Bhamidipati will also serve as a medical oncologist at SCRI Oncology Partners starting October 22. In his new role, Dr. Bhamidipati will work closely with Vivek Subbiah, MD, our Chief of Early-Phase Drug Development, to further enhance our early-phase drug development program in Nashville. Join us in welcoming Dr. Bhamidipati to SCRI! 👏 #SCRI #DrugDevelopment #Oncology  https://lnkd.in/gZcJQj7A

Remember Jimi, one of our amazing CRISPR patients who was featured across many national media outlets? Not only did he reach new healthcare heights with the CRISPR therapy, but he recently reached new heights by summiting Mount Kilimanjaro in September! Jimi, a 39-year-old business owner from Atlanta, is the world’s first patient with sickle cell disease (SCD) to reach the summit of Kilimanjaro. Patients with SCD are at serious risk of complications and death in low-oxygen environments; doctors advise against entering an elevation of 10,000+ feet. Jimi, now functionally cured, summited Kilimanjaro at 19,341 feet! Join us in congratulating Jimi on this amazing accomplishment! #CRISPR #ClinicalTrials #SickleCellDisease #PatientStory #Inspiration #MountKilimanjaro #HealthJourney

We are excited to announce our partnership with BostonGene to integrate their molecular testing and informatics platforms into our network. This collaboration is set to validate novel biomarkers using BostonGene’s AI-powered multiomics platform in real-world cancer populations, enhancing our personalized oncology care. 📌 Learn more: https://lnkd.in/gAtv8649 #Oncology

One in eight women will have breast cancer at some point in their life. This #BreastCancerAwarenessMonth, Erika Hamilton, MD, Chair, Breast Executive Committee Director, Breast Cancer Research Program Sarah Cannon Research Institute, is educating about common breast cancer myths and misconceptions.   Check out what you should know on WKRN News 2. #BreastCancer SCRI Oncology Partners

🩺 How Much Do Diet and Exercise Impact Breast Cancer Risk? Katie Couric Media interviewed Erika Hamilton, MD, Director of Breast Cancer Research at the Sarah Cannon Research Institute and SCRI Oncology Partners, to uncover the facts: 🔹 Exercise: Strong links between maintaining a healthy body weight and reduced post-menopausal breast cancer risk. Regular exercise is beneficial, but not directly causal. 🔹 Diet: Associations suggest lower risk with fruit/vegetable-rich diets vs. high-fat diets. Specific superfoods like flax seeds, berries, and green tea are highly recommended. 🔹 Alcohol: A consistent causal link to higher breast cancer risks. Moderation is key. Dr. Hamilton advises a holistic, balanced approach to diet and exercise. Stay informed, not paranoid. Your lifestyle choices can make a difference, but they’re part of a broader health picture. Read the full article: https://lnkd.in/ebcztPb8 #BreastCancerAwareness #HealthyLiving #DietAndExercise #WomensHealth

Breast cancer outcomes are heavily influenced by when the cancer is detected. This #BreastCancerAwarenessMonth, Erika Hamilton, MD, Director, Breast Cancer Research at Sarah Cannon Research Institute is emphasizing the importance of screening for better outcomes and educating about the promising advancements in treatment. #CancerResearch #BreastCancer #PatientCare 

Important Update: We hope you had the opportunity to watch Good Morning America, where Jenna Fischer's recent breast cancer battle inspired a conversation around early detection and stage 1 triple positive breast cancer treatment. SCRI breast cancer expert, Erika Hamilton, MD, SCRI Oncology Partners, joined the show to share her expertise on the aggressive disease.   Dr. Hamilton’s insights into early detection strategies and the latest advancements in treatment highlight the essential role of targeted therapies and regular screenings play in combating breast cancer. If you missed this important segment, watch it below. https://lnkd.in/dHmKpigG #BreastCancerAwareness #EarlyDetection #AnnualScreening #SCRI #GoodMorningAmerica #JennaFischer